Medicago Planning Vaccine Production Facility in Durham, North Carolina
08/10/2010
"North Carolina's quality of work force, its training programs, and overall understanding of biotech development models were critical factors in our decision to locate in RTP," said Andy Sheldon, president and CEO of Medicago. "We are thrilled with our decision to build our vaccine facility in one of the largest and successful technology parks."
Medicago has received a $21 million research grant from the Defense Advanced Research Projects Agency (DARPA) to improve the production process of H1N1 vaccines. The company's project represents a total investment of more than $32 million in Research Triangle Park.
Project Announcements
Fukoku Korea Plans Henry County, Virginia, Manufacturing Operations
03/13/2026
Germany-Based Sennheiser Group Plans Nashville, Tennessee, Operations
03/12/2026
Interstate Group Expands Giles County, Virginia, Production Operations
03/11/2026
Shinhwa Auto USA Expands Auburn, Alabama, Operations
03/11/2026
General Atomics Expands Shannon, Mississippi, Production Operations
03/11/2026
Starbucks Plans Davidson County, Tennessee, Corporate Operations
03/08/2026
Most Read
-
Top States for Doing Business in 2024: A Continued Legacy of Excellence
Q3 2024
-
What Companies Need from Modern Manufacturing Sites
Q1 2026
-
Economic Developer Role Shifting from Deal-Making to Systems Stewardship
Q1 2026
-
The New Industrial Revolution in Biotech
Q4 2025
-
Capitalizing on the OBBBA Before the 2026 Cliff
Q1 2026
-
The Skilled Trades Are Ready for a Digital Future
Q4 2025
-
Amazon’s First Mass Timber Delivery Station Tests the Future of Low-Carbon Logistics
Q4 2025